{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:52:46Z","timestamp":1777420366518,"version":"3.51.4"},"reference-count":26,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2025,1,12]],"date-time":"2025-01-12T00:00:00Z","timestamp":1736640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Addition of midostaurin to standard \u201c7+3\u201d (cytarabine and anthracycline) significantly prolongs overall and event-free survival. At University of Washington\/Fred Hutchinson Cancer Center (UW\/FHCC), the standard regimen for newly diagnosed (ND) and relapsed\/refractory (R\/R) AML is cladribine, high-dose cytarabine, GCSF, and mitoxantrone (CLAG-M); midostaurin is added if FLT3-mutated. There is limited data on the use of FLT3-inhibitors with high-dose cytarabine regimens in AML.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>This study aimed to evaluate the safety and efficacy of the combination of midostaurin with CLAG-M versus midostaurin plus 7+3 in FLT3-mutated AML patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This is a retrospective, multicenter review including FLT3-mutated AML patients undergoing (re)induction chemotherapy with either CLAG-M or 7+3 at UW\/FHCC, Oregon Health &amp; Science University, and Swedish Cancer Institute. The primary outcome was incidence of adverse events. Secondary outcomes included disease response per ELN2017 criteria and 28-day mortality. Excluded were patients on clinical trials or who started midostaurin 30 days after chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Eighty patients treated from September 2016 to December 2023 were included; 36 patients received CLAG-M, and 44 patients 7+3. Baseline characteristics were similar across all institutions. Adverse event rates were similar between the 2 cohorts, except diarrhea and bleeding which were more common in the 7+3 cohort. The rate of complete remission (CR) plus CR with incomplete blood count recovery did not significantly differ between the 2 cohorts: CLAG-M, 86% versus 7+3, 70% (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.11).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion &amp; relevance:<\/jats:title>\n                    <jats:p>The toxicity profile of CLAG-M combined with midostaurin is comparable with the combination of 7+3 with midostaurin, and induces high remissions rates in adults with FLT3-mutated AML.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280241305608","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:36:49Z","timestamp":1736728609000},"page":"703-713","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of the Toxicity and Outcomes of the Combination of Midostaurin and CLAG-M in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML): A Multicenter Retrospective Analysis"],"prefix":"10.1177","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3389-9756","authenticated-orcid":false,"given":"Ashley","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Pharmacy, UW Medicine, Fred Hutchinson Cancer Center, Seattle, WA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9972-4794","authenticated-orcid":false,"given":"Grace","family":"Baek","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, UW Medicine, Fred Hutchinson Cancer Center, Seattle, WA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn","family":"Russell","sequence":"additional","affiliation":[{"name":"Department of Hematologic Malignancies, Fred Hutchinson Cancer Center, Seattle, WA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carole","family":"Shaw","sequence":"additional","affiliation":[{"name":"Department of Hematologic Malignancies, Fred Hutchinson Cancer Center, Seattle, WA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"Othus","sequence":"additional","affiliation":[{"name":"Department of Statistics, UW Medicine, Seattle, WA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, UW Medicine, Fred Hutchinson Cancer Center, Seattle, WA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shannon","family":"Palmer","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Oregon Health &amp; Science University, Portland, OR, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4372-6074","authenticated-orcid":false,"given":"Jack","family":"Rasmussen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Oregon Health &amp; Science University, Portland, OR, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Bubalo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Oregon Health &amp; Science University, Portland, OR, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tenzin","family":"Tsomo","sequence":"additional","affiliation":[{"name":"Swedish Cancer Institute, Seattle, WA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tenley","family":"Schwarz","sequence":"additional","affiliation":[{"name":"Swedish Cancer Institute, Seattle, WA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swathi","family":"Namburi","sequence":"additional","affiliation":[{"name":"Swedish Cancer Institute, Seattle, WA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Halpern","sequence":"additional","affiliation":[{"name":"Department of Hematologic Malignancies, Fred Hutchinson Cancer Center, Seattle, WA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,1,12]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.5045\/br.2015.50.4.204"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-733196"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017011080"},{"key":"e_1_3_3_5_2","unstructured":"RYDAPT (midostaurin) [package insert]. Novartis Pharmaceuticals Corporation; 2023."},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.45765"},{"key":"e_1_3_3_7_2","unstructured":"XOSPATA (gilteritinib) [package insert]. Astellas Pharma US Inc.; 2022."},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01061"},{"key":"e_1_3_3_9_2","unstructured":"VANFLYTA (quizartinib) [package insert]. Daiichi Sankyo Inc.; 2024."},{"key":"e_1_3_3_10_2","unstructured":"NEXAVAR (sorafenib) [package insert]. Bayer Healthcare Pharmaceuticals Inc.; 2023."},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614359"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S177894"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-782292"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-113582"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26822"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0135-8"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17974"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.4874"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010392"},{"key":"e_1_3_3_20_2","unstructured":"US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Published 2017. Accessed December 12 2024. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e31829b1d2a"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-016-0348-8"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-273243"},{"issue":"4","key":"e_1_3_3_24_2","first-page":"154","volume":"14","author":"The oncology pipeline overview: recent approvals and near-term drugs","year":"2021","unstructured":"The oncology pipeline overview: recent approvals and near-term drugs. Am Health Drug Benefits. 2021;14(4):154-155.","journal-title":"Am Health Drug Benefits"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2023.03.002"},{"key":"e_1_3_3_26_2","unstructured":"NCCN guidelines: antiemesis (Version 2.2024). Accessed December 12 2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","unstructured":"Hesketh PJ Kris MG Basch E et al. Antiemetics: ASCO guideline update. JCO. 2020;38(24):2782-2797. doi:10.1200\/JCO.20.01296","DOI":"10.1200\/JCO.20.01296"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280241305608","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280241305608","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280241305608","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:13:58Z","timestamp":1777374838000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280241305608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,12]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1177\/10600280241305608"],"URL":"https:\/\/doi.org\/10.1177\/10600280241305608","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,12]]}}}